Interferon beta-1b
- Generic Name
- Interferon beta-1b
- Brand Names
- Betaferon, Betaseron, Extavia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145155-23-3
- Unique Ingredient Identifier
- TTD90R31WZ
- Background
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
- Indication
Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-11-16
- Target Recruit Count
- 75
- Registration Number
- NCT00176592
- Locations
- ๐บ๐ธ
New Jersey Medical School, Newark, New Jersey, United States
The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002299
- Locations
- ๐บ๐ธ
UCI Med Ctr, Orange, California, United States
๐บ๐ธUniv of California / San Diego Treatment Ctr, San Diego, California, United States
๐บ๐ธUSC, Los Angeles, California, United States
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Bayer
- Registration Number
- NCT00002238
- Locations
- ๐บ๐ธ
Alta Bates / Herrick Hosp, Berkeley, California, United States
๐บ๐ธUSC School of Medicine / Norris Cancer Hosp, Los Angeles, California, United States
๐บ๐ธCedars Sinai Med Ctr, Los Angeles, California, United States
Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 36
- Registration Number
- NCT00000695
- Locations
- ๐บ๐ธ
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
๐บ๐ธUCLA CARE Ctr, Los Angeles, California, United States
๐บ๐ธNorthwestern Univ Med School, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.